Strategic Facility Expansion Vibalogics has significantly expanded its manufacturing capacity in the Boston area with a new 118,000-square-foot facility and a substantial $150 million investment, indicating a strong commitment to supporting large-scale virotherapy projects and an increased capacity for high-volume production.

Recent Acquisition Strengthening Capabilities The acquisition by Recipharm in February 2022 enhances Vibalogics' global reach and technological expertise in biologics manufacturing, creating opportunities for collaborative projects and expanding their service offerings to international clients.

Growing Workforce for Service Scalability With plans to add over 100 employees, Vibalogics demonstrates a focus on scaling operational capacity and improving customer support, making it an attractive partner for companies seeking reliable manufacturing and development services in the biotech sector.

Specialized Expertise in Virotherapy Vibalogics specializes in virotherapies such as gene therapies, viral vectors, and vaccines across a broad spectrum of viruses, providing opportunities to engage with innovative biopharma companies developing cutting-edge virology treatments.

Focus on Customer-centric Services Their transparent, flexible, and communication-forward approach positions Vibalogics as a dependable partner for clients seeking tailored manufacturing solutions, offering potential for collaborative opportunities and repeat business in the biologics space.